• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

How targeting metabolism can defeat cancer stem cells

Bioengineer by Bioengineer
July 3, 2018
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Michigan Medicine

ANN ARBOR, Michigan — Researchers are the University of Michigan Rogel Cancer are unraveling a crucial thread that explains why cancer so often becomes resistant to treatment.

In a breakthrough finding in 2003, Max S. Wicha, M.D., and colleagues discovered that a small number of cells within a tumor – the cancer stem cells – were responsible for fueling the growth and spread of cancer. Kill the stem cells, and you could master the cancer.

But cancer is like a game of whack-a-mole. Strike it down in one place and it pops back up in another.

Now, researchers have found that cancer stem cells exist in more than one state and are very plastic, meaning they can change form, sliding back and forth between a dormant state and a rapidly growing state. This plasticity is responsible for cancer's two key characteristics: multiplying and spreading.

"When we use targeted therapies, they often only work for a certain period of time, and then the cancer becomes resistant. A lot of that resistance is from the cancer stem cells. They change form to evade the targeted therapy," says Wicha, Madeline and Sidney Forbes Professor of Oncology and director of the Forbes Institute for Cancer Discovery at the Rogel Cancer Center.

"This tells us we're going to need multiple stem cell therapies to attack multiple forms of stem cells," he says.

It turns out the cell metabolism controls this change, suggesting a possible way in to attack the stem cells.

Cells get energy through mitochondria, which depends on oxygen, and through sugar, or glucose. Cancer stem cells pull energy both ways. In the dormant state, it uses glucose; in the proliferative state it depends on oxygen.

So researchers attacked the metabolism in both ways. They used a drug currently used to treat arthritis that's known to block mitochondria, and they manipulated glucose to block that path. They tested this in mice with breast cancer and found they were able to knock out the stem cells. Results are published in Cell Metabolism.

"Rather than just try to use toxic chemicals to kill a cell, we use the metabolism of the cell itself to kill the cancer," Wicha says.

Researchers are also understanding that the immune system is regulated by metabolism, suggesting the possibility of combining anti-stem cell therapies with immunotherapies.

Researchers hope to bring this concept to the clinic in the next few years.

###

Additional authors: Ming Luo, Li Shang, Michael D. Brooks, Evelyn Jiagge, Yongyou Zhu, Johanna M. Buschhaus, Sarah Conley, Melissa A. Fath, April Davis, Elizabeth Gheordunescu, Yongfang Wang, Ramdane Harouaka, Ann Lozier, Daniel Triner, Sean McDermott, Sofia D. Merajver, Gary D. Luker, Douglas R. Spitz

Funding: University of Michigan Forbes Institute for Cancer Discovery, National Cancer Institute grants R01 CA101860, R35 CA129765, R01 CA182804, P30 CA086862, R01 CA196018, U01 CA210152

Disclosure: Wicha holds equity in OncoMed Pharmaceuticals

Reference: Cell Metabolism, doi:10.1016/j.cmet.2018.06.006

Resources:

University of Michigan Rogel Cancer Center, http://www.rogelcancercenter.org

Michigan Medicine Cancer AnswerLine, 800-865-1125

Michigan Health Lab, http://www.MichiganHealthLab.org

Media Contact

Nicole Fawcett
[email protected]
734-764-2220
@umichmedicine

http://www.med.umich.edu

Related Journal Article

http://dx.doi.org/10.1016/j.cmet.2018.06.006

Share12Tweet8Share2ShareShareShare2

Related Posts

Deep Learning Uncovers Tetrahydrocarbazoles as Potent Broad-Spectrum Antitumor Agents with Click-Activated Targeted Cancer Therapy Approach

February 7, 2026

Newly Discovered Limonoid DHL-11 from Munronia henryi Targets IMPDH2 to Combat Triple-Negative Breast Cancer

February 7, 2026

New Discovery Reveals Why Ovarian Cancer Spreads Rapidly in the Abdomen

February 6, 2026

New Study Finds Americans Favor In-Clinic Screening Over At-Home Tests for Cervical Cancer

February 6, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Palmitoylation of Tfr1 Drives Platelet Ferroptosis and Exacerbates Liver Damage in Heat Stroke

Oxygen-Enhanced Dual-Section Microneedle Patch Improves Drug Delivery and Boosts Photodynamic and Anti-Inflammatory Treatment for Psoriasis

Scientists Identify SARS-CoV-2 PLpro and RIPK1 Inhibitors Showing Potent Synergistic Antiviral Effects in Mouse COVID-19 Model

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.